As of June 18, 2025, Anika Therapeutics Inc (ANIK) reports a EV/EBITDA of -4.35.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Anika Therapeutics Inc's EV/EBITDA to Peers
To better understand Anika Therapeutics Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Anika Therapeutics Inc (ANIK) | -4.35 |
| ADMA Biologics Inc (ADMA) | 28.46 |
| MannKind Corp (MNKD) | 19.57 |
| Abbvie Inc (ABBV) | 17.90 |
| Amgen Inc (AMGN) | 15.21 |
| Theratechnologies Inc (TH.TO) | 14.66 |
Compared to its competitors, Anika Therapeutics Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.